Literature DB >> 11104194

Estrogen use among nursing home residents with a diagnosis of Parkinson's disease.

H H Fernandez1, K L Lapane.   

Abstract

BACKGROUND: The role of estrogen in motor, cognitive, and behavioral functions in Parkinson's disease (PD) remains unclear. OBJECTIVES/
METHODS: To determine differences in functional, cognitive, and behavioral patterns between estrogen users and non-users, we performed an observational study on 10,145 elderly women with PD using the Systematic Assessment in Geriatric drug use via Epidemiology (SAGE) database. The SAGE database consists of the Minimum Data Set (MDS), data collected on a cross-section of over 400,000 nursing home (NH) residents in five US states. Using a cross-sectional study design, we evaluated the demographics, physical and cognitive function, and mortality rates of women with PD who received estrogen (n = 195) versus those who did not receive estrogen (n = 9950).
RESULTS: Independent of age, estrogen users were less cognitively impaired and more independent in their activities of daily living. Surprisingly, more estrogen users were depressed and more likely to be on an antidepressant than non-users. One-year death rates were comparable between estrogen users and non-users.
CONCLUSION: This study supports the growing number of recent data suggesting estrogen's potential beneficial effects on PD motor and cognitive functions.

Entities:  

Mesh:

Year:  2000        PMID: 11104194     DOI: 10.1002/1531-8257(200011)15:6<1119::aid-mds1009>3.0.co;2-0

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

Review 1.  Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

Authors:  Dean Dluzen; Martin Horstink
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

2.  Symptom Dimensions of Depression and Apathy and Their Relationship With Cognition in Parkinson's Disease.

Authors:  Sarah M Szymkowicz; Vonetta M Dotson; Jacob D Jones; Michael S Okun; Dawn Bowers
Journal:  J Int Neuropsychol Soc       Date:  2017-10-16       Impact factor: 2.892

Review 3.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

Review 4.  Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease?

Authors:  Julia Heller; Imis Dogan; Jörg B Schulz; Kathrin Reetz
Journal:  Aging Dis       Date:  2013-10-22       Impact factor: 6.745

5.  Does glitazone treatment have a role on the prevention of Parkinson's disease in adult diabetic population? A systematic review.

Authors:  Jesús D Meléndez-Flores; Juan Manuel Millán-Alanís; Adrián González-Martínez; Neri Alejandro Álvarez-Villalobos; Ingrid Estrada-Bellmann
Journal:  Metab Brain Dis       Date:  2020-05-04       Impact factor: 3.584

6.  Hormone replacement therapy and risk for neurodegenerative diseases.

Authors:  Richelin V Dye; Karen J Miller; Elyse J Singer; Andrew J Levine
Journal:  Int J Alzheimers Dis       Date:  2012-04-04

Review 7.  The role of estrogen in the treatment of men with schizophrenia.

Authors:  Jayashri Kulkarni; Emmy Gavrilidis; Roisin Worsley; Tamsyn Van Rheenen; Emily Hayes
Journal:  Int J Endocrinol Metab       Date:  2013-07-01

8.  The Effect of Estrogen Replacement Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A Meta-Analysis.

Authors:  Yu-Jia Song; Shu-Ran Li; Xiao-Wan Li; Xi Chen; Ze-Xu Wei; Qing-Shan Liu; Yong Cheng
Journal:  Front Neurosci       Date:  2020-03-10       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.